Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a clinical trial.
Amizon
Covid-19
FAV00A
RNA polymerase
SARS-CoV-2
molecular dynamics simulation
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
21 Jan 2021
21 Jan 2021
Historique:
pubmed:
21
1
2021
medline:
21
1
2021
entrez:
20
1
2021
Statut:
epublish
Résumé
Pandemic SARS-CoV-2 causes a mild to severe respiratory disease called Coronavirus Disease 2019 (COVID-19). Control of SARS-CoV-2 spread will depend on vaccine-induced or naturally acquired protective herd immunity. Until then, antiviral strategies are needed to manage COVID-19, but approved antiviral treatments, such as remdesivir, can only be delivered intravenously. Enisamium (laboratory code FAV00A, trade name Amizon®) is an orally active inhibitor of influenza A and B viruses in cell culture and clinically approved in countries of the Commonwealth of Independent States. Here we show that enisamium can inhibit SARS-CoV-2 infections in NHBE and Caco-2 cells.
Identifiants
pubmed: 33469600
doi: 10.1101/2021.01.05.21249237
pmc: PMC7814846
pii:
doi:
Types de publication
Preprint
Langues
eng
Commentaires et corrections
Type : UpdateIn
Déclaration de conflit d'intérêts
Conflict of interest V.M. and A.G. are employees of Farmak Public Joint Stock Company, Kiev, Ukraine. Part of this research was funded by Farmak Public Joint Stock Company, Kiev, Ukraine.
Références
Nucleic Acids Res. 2010 Jan;38(1):203-14
pubmed: 19875418
Antimicrob Agents Chemother. 2021 Mar 18;65(4):
pubmed: 33558285
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
pubmed: 8744570
Sci Transl Med. 2020 Apr 29;12(541):
pubmed: 32253226
Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):11613-11618
pubmed: 30352857
Ter Arkh. 2020 Dec 26;92(11):45-50
pubmed: 33720603
Science. 2020 Jun 26;368(6498):1499-1504
pubmed: 32358203
Nature. 2020 Jul;583(7816):469-472
pubmed: 32408336
Cell. 2020 Sep 17;182(6):1560-1573.e13
pubmed: 32783916
Nat Commun. 2020 Sep 17;11(1):4682
pubmed: 32943628
J Comput Chem. 2005 Dec;26(16):1668-88
pubmed: 16200636
J Comput Chem. 2009 Dec;30(16):2785-91
pubmed: 19399780
Nature. 2020 Aug;584(7819):154-156
pubmed: 32438371
Nat Commun. 2020 Nov 18;11(1):5874
pubmed: 33208736
J Comput Chem. 2005 Dec;26(16):1781-802
pubmed: 16222654
Cells. 2020 Oct 30;9(11):
pubmed: 33143316
J Med Chem. 2006 Nov 2;49(22):6596-606
pubmed: 17064078
Stat Med. 2011 Dec 10;30(28):3267-84
pubmed: 22105690
Int J Mol Sci. 2020 Jun 20;21(12):
pubmed: 32575728
J Biol Chem. 2020 Sep 11;295(37):12910-12934
pubmed: 32661197
Antiviral Res. 2014 Jan;101:122-30
pubmed: 24269475
BMC Med Res Methodol. 2013 Jul 19;13:94
pubmed: 23870495
Nat Microbiol. 2021 Jan;6(1):11-18
pubmed: 33273742
Antivir Chem Chemother. 2018 Jan-Dec;26:2040206618811416
pubmed: 30466301
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):E3900-9
pubmed: 25197083